Lyfgenia (lovotibeglogene autotemcel)
An approved treatment for Sickle Cell Disease.
The same compound appears under different names depending on the context. Here is how to identify Lovotibeglogene autotemcel wherever you encounter it, plus the key facts at a glance.
- Generic name
- Lovotibeglogene autotemcel
- Brand name
- Lyfgenia
- Development codes
- LentiGlobin BB305, bb1111
- Drug class
- Gene therapy
- Manufacturer
- Genetix Biotherapeutics (formerly bluebird bio)
- How it's taken
- Similar to Casgevy: stem cell collection, gene modification at a central facility, chemotherapy conditioning, then single IV infusion.
A gene therapy for sickle cell disease that modifies a patient's own stem cells to produce a form of hemoglobin (HbAT87Q) that prevents red blood cells from sickling.
We'll email you when Lyfgenia's FDA label changes, when the FDA acts on it, and when new trials for Sickle Cell Disease open. Unsubscribe anytime.
Where Lovotibeglogene autotemcel fits
Gene addition therapy for sickle cell disease in patients 12 and older with a history of vaso-occlusive events, adding a modified beta-globin gene. People who also carry a specific alpha-thalassemia trait (2 deleted alpha-globin genes, -α3.7/-α3.7) may develop anemia afterward that needs ongoing blood transfusions, and it has not been studied in people with more than 2 alpha-globin gene deletions. An alternative to exagamglogene autotemcel (Casgevy), using gene addition rather than gene editing.
How Lovotibeglogene autotemcel works
Doctors collect a patient's blood stem cells and use a lentiviral vector to insert a modified beta-globin gene. This gene produces HbAT87Q, a therapeutic hemoglobin designed to interfere with the sickling process. After chemotherapy conditioning, the modified cells are infused back, and they produce red blood cells with the anti-sickling hemoglobin.
Mechanism: Lentiviral gene therapy that adds a modified beta-globin gene to produce anti-sickling hemoglobin
Side effects and safety
Carries a black box warning for hematologic malignancy risk (blood cancer). Side effects from chemotherapy conditioning include low blood counts, mouth sores, nausea, and infection risk. Infertility from conditioning is a significant concern. Lifelong cancer monitoring required, including blood counts at least every 6 months for at least 15 years. The label also warns that platelets can be slow to recover after the infusion, raising the risk of bleeding, and that the new cells may fail to take hold, in which case backup (rescue) cells are given, so blood counts are checked often until they recover. It also warns about allergic reactions during the infusion, says hydroxyurea, iron chelation and HIV medicines must be stopped for set times before stem cell collection and conditioning, and notes that treated patients can test falsely positive on PCR-based HIV tests.
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking Lovotibeglogene autotemcel
Similar to Casgevy: stem cell collection, gene modification at a central facility, chemotherapy conditioning, then single IV infusion. Requires extended hospitalization at a certified treatment center.
Availability and cost
Only available as the brand-name product.
Lentiviral gene therapy requiring stem cell collection, ex vivo gene addition, myeloablative conditioning, and transplantation. One-time curative-intent treatment with complex individualized manufacturing.
Help paying for Lyfgenia
Pick your insurance to see which help fits. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE; charity funds are the usual route there.
- Insurance and case manager help
Free support program with a dedicated Patient Navigator who helps find a treatment center, explains insurance coverage and costs, and coordinates logistics.
The official page does not say who qualifies. Ask the program. · source - Travel help
Travel and accommodation assistance is offered through the program.
The official page does not say who qualifies. Ask the program. · source - Other support
Financial and logistical support for fertility preservation.
The official page does not say who qualifies. Ask the program. · source
Good to know: bluebird bio is now Genetix Biotherapeutics. Official pages do not say who qualifies for travel or fertility support, and no copay program is described. The program formerly called my bluebird support is now Genetix CARES.
- From a charity · The Assistance FundSickle Cell Disease fundWaitlist
Pays for: Copays, coinsurance, deductibles and other health-related expenses.
The foundation says: “WAITLIST — Accepting Waitlist Patients. TAF is currently accepting requests to join the enrollment waitlist for this program. Waitlists a…”
Clinical trial results
88% of patients (28 of 32) achieved complete resolution of vaso-occlusive events within 6-18 months post-infusion. Approved December 8, 2023, on the same day as Casgevy.
Development history
Developed by bluebird bio as part of their lentiviral gene therapy platform. Approved December 8, 2023. The hematologic malignancy warning has been a factor in adoption decisions, as patients weigh the cancer risk against the potential for a functional cure.
Explore Sickle Cell Disease trials
Other Sickle Cell Disease treatments
Lovotibeglogene autotemcel in Trial Friend News and Guides
Common questions about Lovotibeglogene autotemcel
▸What is Lovotibeglogene autotemcel (Lyfgenia)?
A gene therapy for sickle cell disease that modifies a patient's own stem cells to produce a form of hemoglobin (HbAT87Q) that prevents red blood cells from sickling.
▸How does Lovotibeglogene autotemcel work?
Doctors collect a patient's blood stem cells and use a lentiviral vector to insert a modified beta-globin gene. This gene produces HbAT87Q, a therapeutic hemoglobin designed to interfere with the sickling process. After chemotherapy conditioning, the modified cells are infused back, and they produce red blood cells with the anti-sickling hemoglobin.
▸What are the side effects of Lovotibeglogene autotemcel?
Carries a black box warning for hematologic malignancy risk (blood cancer). Side effects from chemotherapy conditioning include low blood counts, mouth sores, nausea, and infection risk. Infertility from conditioning is a significant concern. Lifelong cancer monitoring required, including blood counts at least every 6 months for at least 15 years. The label also warns that platelets can be slow to recover after the infusion, raising the risk of bleeding, and that the new cells may fail to take hold, in which case backup (rescue) cells are given, so blood counts are checked often until they recover. It also warns about allergic reactions during the infusion, says hydroxyurea, iron chelation and HIV medicines must be stopped for set times before stem cell collection and conditioning, and notes that treated patients can test falsely positive on PCR-based HIV tests.
▸How is Lovotibeglogene autotemcel taken?
Similar to Casgevy: stem cell collection, gene modification at a central facility, chemotherapy conditioning, then single IV infusion. Requires extended hospitalization at a certified treatment center.
▸Is Lovotibeglogene autotemcel FDA approved?
Yes, Lovotibeglogene autotemcel (Lyfgenia) is FDA approved (2023) for the treatment of Sickle Cell Disease.
▸What is the black box warning on Lyfgenia?
Lyfgenia carries a black box warning for hematologic malignancy risk (blood cancer). Cases of myelodysplastic syndrome and acute myeloid leukemia have been reported in patients treated with lentiviral vector gene therapies. Lifelong cancer monitoring is required after treatment.
▸How does Lyfgenia differ from Casgevy?
Lyfgenia uses a lentiviral vector to add a modified beta-globin gene (producing HbAT87Q), while Casgevy uses CRISPR to edit existing genes to boost fetal hemoglobin. Both aim to prevent sickling, but through different mechanisms. Lyfgenia's blood cancer warning is a factor in treatment selection.
▸What is HbAT87Q?
HbAT87Q is a therapeutic hemoglobin produced by the modified beta-globin gene delivered by Lyfgenia. It is specifically designed to interfere with the sickling process, preventing the abnormal hemoglobin S from forming the rigid polymers that deform red blood cells.
▸How effective is Lyfgenia for sickle cell disease?
In clinical trials, 88% of patients (28 of 32) achieved complete resolution of vaso-occlusive events within 6-18 months after infusion. This represents a significant reduction in the painful crises that characterize sickle cell disease.
▸What is the treatment timeline for Lyfgenia?
The process includes stem cell collection, gene modification at a central manufacturing facility (which takes several months), chemotherapy conditioning, then a single IV infusion. Extended hospitalization at a certified treatment center is required during and after the infusion.
▸How does the cancer risk factor into treatment decisions?
The hematologic malignancy warning is a significant consideration. Patients and their doctors weigh the cancer risk against the potential for a functional cure of sickle cell disease. Some patients may prefer Casgevy, which does not carry this warning, while others may choose Lyfgenia based on individual clinical factors.
▸What support does Genetix Biotherapeutics provide for Lyfgenia patients?
Genetix CARES (formerly my bluebird support) provides personalized assistance, educational resources, and answers to patient questions throughout the treatment process at no cost to patients and caregivers.